We are pleased to announce that we have signed a business alliance agreement (hereinafter referred to as “the contract”) for business development in the regenerative medicine and healthcare areas by combining Gene Techno Science Co., Ltd. (TSE Mothers Securities Code: 4584) with the business bases of both parties. Details are as follows.

１．Objectives of the Contract

In April 2019, we transitioned to a group holding company structure, and while exerting the synergy effect of the group companies, we are working on business expansion in a wide range of life science and healthcare industries. This partnership will be implemented in the regenerative medicine business, which is currently positioned as one of our main businesses, with the aim of further strengthening the technology development system in the future by collaborating with external partners.

Gene Techno Science Co., Ltd., a partner of this agreement, aims to maximize its know-how and knowledge on biotechnology with the goal of GTS3.0, an engineering company that creates value with biotechnology, aiming for a new business stage from 2018. In addition to the rare diseases and intractable diseases that we have been dealing with, we have focused on pediatric diseases as a priority target, and provide comprehensive care including patients suffering from these diseases, their families and caregivers. Aiming to develop new medicines as well as new medicines.

We believe that it would be best to build a stronger cooperative relationship, as both parties agreed that the new business development combining Gene Techno Science Co., Ltd. and our business foundation would improve the corporate value of both parties. Therefore, we have concluded this contract. Going forward, we will continue specific discussions aimed at strengthening collaboration, work to further expand our business, and make efforts to accelerate our business development.

２．Company Description

• Company Name：Gene Techno Science Co., Ltd
• Headquarter：Kanayama BLDG 3F, 1-2-12, Shinkaw, Chuo-ku, Tokyo, JAPAN
• Representative：Masaharu Tani, President & CEO
• Business：Development of bio pharmaceuticals using regenerative medicine technologies
• Capital：JPY 611MM （as of September 30^th, 2019）